论文部分内容阅读
目的探讨奥扎格雷钠联合低分子肝素钙治疗短暂性脑缺血发作的临床效果。方法 80例短暂性脑缺血发作患者,依据治疗方法将其分为研究组和对照组,各40例。给予对照组患者单纯低分子肝素钙治疗,给予研究组患者奥扎格雷钠联合低分子肝素钙治疗。比较两组患者的临床疗效及不良反应发生情况。结果研究组患者治疗的总有效率为95.0%(38/40)显著高于对照组的82.5%(33/40),差异具有统计学意义(P<0.05);研究组与对照组患者的不良反应发生率分别为7.5%(3/40)、10.0%(4/40),比较差异无统计学意义(P>0.05)。结论奥扎格雷钠联合低分子肝素钙治疗短暂性脑缺血发作的临床疗效显著,且不会增加患者的不良反应,具有较高的安全性,值得推广。
Objective To investigate the clinical effect of sodium ozagrel combined with low molecular weight heparin on transient ischemic attack. Methods Eighty patients with transient ischemic attack were divided into study group and control group according to the treatment method, 40 cases in each. Patients in the control group were treated with low molecular weight heparin alone, and patients in the study group were treated with ozagrel sodium and low molecular weight heparin calcium. The clinical efficacy and adverse reactions of the two groups were compared. Results The total effective rate of study group was 95.0% (38/40), which was significantly higher than that of control group (82.5%, 33/40) (P <0.05). The study group and control group The incidence of reaction was 7.5% (3/40) and 10.0% (4/40) respectively, with no significant difference (P> 0.05). Conclusion Ozagrel sodium combined with low molecular weight heparin calcium treatment of transient ischemic attack significant clinical efficacy, and does not increase the adverse reactions in patients with high safety, it is worth promoting.